Clinical Research and Standard of Care—An Unresolved Question?
| Autor: | Gerhard Fortwengel, Firas Fneish, Nadia G. Tornieporth |
|---|---|
| Jazyk: | angličtina |
| Předmět: |
Pharmacology
medicine.medical_specialty Standard of care business.industry lcsh:RM1-950 Alternative medicine Bioethics Clinical trial lcsh:Therapeutics. Pharmacology Clinical research Medicine Pharmacology (medical) Engineering ethics Element (criminal law) business Psychiatry Emerging markets Declaration of Helsinki |
| Zdroj: | Current Therapeutic Research, Vol 78, Iss S, Pp S4-S5 (2016) |
| ISSN: | 0011-393X |
| DOI: | 10.1016/j.curtheres.2016.05.011 |
| Popis: | Ever since the 1996 revision of the Declaration of Helsinki, the World Medical Association has attempted to address ethical and scientific concerns of its diverse stakeholders for Articles 33 (use of placebo) and 34 (posttrial provisions), most recently in 2013. Both are inextricably linked to standard of care, an essential element of any comparative, interventional clinical trial. But has this now 20-year-long ethical debate truly been put to rest? The choice of standard of care in clinical trials remains a complex issue, particularly for comparative trials conducted in emerging countries. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|